February 13, 2018 / 6:41 AM / 2 months ago

BRIEF-Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase​

Feb 13 (Reuters) - ERYTECH PHARMA SA:

* ‍ERYTECH SELECTS TRIPLE NEGATIVE BREAST CANCER AS NEXT INDICATION FOR ERYASPASE​

* ‍SET-UP ACTIVITIES FOR PHASE 2 CLINICAL STUDY ONGOING, PATIENT ENROLLMENT EXPECTED TO START Q3 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below